YTHDF1 and neoplasm: observed that YTHDF1‐deficient mice undergoing PD‐L1 blockade exhibited more extensive tumour regression than untreated YTHDF1−/− or WT mice subjected to anti‐PD‐L1 therapy, suggesting that YTHDF1 as a potential anti‐tumour immunotherapy target.